|
1
|
Clark JC, Dass CR and Choong PF: A review
of clinical and molecular prognostic factors in osteosarcoma. J
Cancer Res Clin Oncol. 134:281–297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Geller DS and Gorlick R: Osteosarcoma: A
review of diagnosis, management, and treatment strategies. Clin Adv
Hematol Oncol. 8:705–718. 2010.PubMed/NCBI
|
|
3
|
Cortini M, Avnet S and Baldini N:
Mesenchymal stroma: Role in osteosarcoma progression. Cancer Lett.
405:90–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsiambas E, Fotiades PP, Sioka C,
Kotrotsios D, Gkika E, Fotopoulos A, Mastronikolis SN, Armata IE,
Giotakis E and Ragos V: Novel molecular and metabolic aspects in
osteosarcoma. J BUON. 22:1595–1598. 2017.PubMed/NCBI
|
|
5
|
Zhou L, Ma X, Yue J, Chen T, Wang XY, Wang
ZW, Pan J and Lin Y: The diagnostic effect of serum miR-139-5p as
an indicator in osteosarcoma. Cancer Biomark. 23:561–567. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen Z, Zhao G, Zhang Y, Ma Y, Ding Y and
Xu N: MiR-199b-5p promotes malignant progression of osteosarcoma by
regulating HER2. J BUON. 23:1816–1824. 2018.PubMed/NCBI
|
|
7
|
Liu JL, Li J, Xu JJ, Xiao F, Cui PL, Qiao
ZG, Chen XD, Tao WD and Zhang XL: MiR-144 inhibits tumor growth and
metastasis in osteosarcoma via dual-suppressing RhoA/ROCK1
signaling pathway. Mol Pharmacol. 95:451–461. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deng Y, Li Y, Fang Q, Luo H and Zhu G:
microRNA-744 is downregulated in glioblastoma and inhibits the
aggressive behaviors by directly targeting NOB1. Am J Cancer Res.
8:2238–2253. 2018.PubMed/NCBI
|
|
9
|
Zhou W, Li Y, Gou S, Xiong J, Wu H, Wang
C, Yan H and Liu T: MiR-744 increases tumorigenicity of pancreatic
cancer by activating Wnt/β-catenin pathway. Oncotarget.
6:37557–37569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tan YL, Bai ZG, Zou WL, Ma XM, Wang TT,
Guo W, Liu J, Li JS, Jie-Yin, Zang YJ, et al: miR-744 is a
potential prognostic marker in patients with hepatocellular
carcinoma. Clin Res Hepatol Gastroenterol. 39:359–365. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Y, Hu CF, Chen J, Yan LX, Zeng YX
and Shao JY: LATS2 is de-methylated and overexpressed in
nasopharyngeal carcinoma and predicts poor prognosis. BMC Cancer.
10:5382010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, Pei J, Xia H, Ke H, Wang H and Tao
W: Lats2, a putative tumor suppressor, inhibits G1/S transition.
Oncogene. 22:4398–4405. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ke H, Pei J, Ni Z, Xia H, Qi H, Woods T,
Kelekar A and Tao W: Putative tumor suppressor Lats2 induces
apoptosis through downregulation of Bcl-2 and Bcl-x(L). Exp Cell
Res. 298:329–338. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dai X, She P, Chi F, Feng Y, Liu H, Jin D,
Zhao Y, Guo X, Jiang D, Guan KL, et al: Phosphorylation of
angiomotin by Lats1/2 kinases inhibits F-actin binding, cell
migration, and angiogenesis. J Biol Chem. 288:34041–34051. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee KH, Goan YG, Hsiao M, Lee CH, Jian SH,
Lin JT, Chen YL and Lu PJ: MicroRNA-373 (miR-373)
post-transcriptionally regulates large tumor suppressor, homolog 2
(LATS2) and stimulates proliferation in human esophageal cancer.
Exp Cell Res. 315:2529–2538. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Han LL, Yin XR and Zhang SQ: miR-103
promotes the metastasis and EMT of hepatocellular carcinoma by
directly inhibiting LATS2. Int J Oncol. 53:2433–2444.
2018.PubMed/NCBI
|
|
17
|
Livak KJ and Scmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cai H, Miao M and Wang Z: miR-214-3p
promotes the proliferation, migration and invasion of osteosarcoma
cells by targeting CADM1. Oncol Lett. 16:2620–2628. 2018.PubMed/NCBI
|
|
19
|
Li W, Meng Z, Zou T, Wang G, Su Y, Yao S
and Sun X: MiR-374a activates Wnt/β-catenin signaling to promote
osteosarcoma cell migration by targeting WIF-1. Pathol Oncol Res.
Dec 6–2018.(Epub ahead of print). View Article : Google Scholar
|
|
20
|
Yu Q, Zhang F, Du Z and Xiang Y:
Up-regulation of serum miR-744 predicts poor prognosis in patients
with nasopharyngeal carcinoma. Int J Clin Exp Med. 8:13296–13302.
2015.PubMed/NCBI
|
|
21
|
Miyamae M, Komatsu S, Ichikawa D,
Kawaguchi T, Hirajima S, Okajima W, Ohashi T, Imamura T, Konishi H,
Shiozaki A, et al: Plasma microRNA profiles: Identification of
miR-744 as a novel diagnostic and prognostic biomarker in
pancreatic cancer. Br J Cancer. 113:1467–1476. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li C, Jia L, Yu Y and Jin L: Lactic acid
induced microRNA-744 enhances motility of SiHa cervical cancer
cells through targeting ARHGAP5. Chem Biol Interact. 298:86–95.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang M and Li H, Zhang Y and Li H:
Oncogenic miR-744 promotes prostate cancer growth through direct
targeting of LKB1. Oncol Lett. 17:2257–2265. 2019.PubMed/NCBI
|
|
24
|
Guan H, Liu C, Fang F, Huang Y, Tao T,
Ling Z, You Z, Han X, Chen S, Xu B, et al: MicroRNA-744 promotes
prostate cancer progression through aberrantly activating
Wnt/β-catenin signaling. Oncotarget. 8:14693–14707. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang C, Zong J, Li Y, Wang X, Du W and Li
L: MiR-744-3p regulates keratinocyte proliferation and
differentiation via targeting KLLN in psoriasis. Exp Dermatol.
28:283–291. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vislovukh A, Kratassiouk G, Porto E,
Gralievska N, Beldiman C, Pinna G, El'skaya A, Harel-Bellan A,
Negrutskii B and Groisman I: Proto-oncogenic isoform A2 of
eukaryotic translation elongation factor eEF1 is a target of
miR-663 and miR-744. Br J Cancer. 108:2304–2311. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fang L, Du WW, Yang W, Rutnam ZJ, Peng C,
Li H, O'Malley YQ, Askeland RW, Sugg S, Liu M, et al: MiR-93
enhances angiogenesis and metastasis by targeting LATS2. Cell
Cycle. 11:4352–4365. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cho WJ, Shin JM, Kim JS, Lee MR, Hong KS,
Lee JH, Koo KH, Park JW and Kim KS: miR-372 regulates cell cycle
and apoptosis of ags human gastric cancer cell line through direct
regulation of LATS2. Mol Cells. 28:521–527. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zheng YB, Xiao K, Xiao GC, Tong SL, Ding
Y, Wang QS, Li SB and Hao ZN: MicroRNA-103 promotes tumor growth
and metastasis in colorectal cancer by directly targeting LATS2.
Oncol Lett. 12:2194–2200. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gao Y, Yi J, Zhang K, Bai F, Feng B, Wang
R, Chu X, Chen L and Song H: Downregulation of MiR-31 stimulates
expression of LATS2 via the hippo pathway and promotes
epithelial-mesenchymal transition in esophageal squamous cell
carcinoma. J Exp Clin Cancer Res. 36:1612017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Feng S, Pan W, Jin Y and Zheng J: MiR-25
promotes ovarian cancer proliferation and motility by targeting
LATS2. Tumour Biol. 35:12339–12344. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Han LL, Yin XR and Zhang SQ: miR-650
promotes the metastasis and epithelial-mesenchymal transition of
hepatocellular carcinoma by directly inhibiting LATS2 expression.
Cell Physiol Biochem. 51:1179–1192. 2018. View Article : Google Scholar : PubMed/NCBI
|
